Concerta, the generic drug prescribed for Attention Deficit Disorder (ADD) had some side effects on patients. The Food and Drug Administration announced it had concerns about whether two approved generic versions of Concerta were in fact therapeutically equivalent to the name-brand drug.
"Two of these generics, so to speak, were not exactly providing the same rate and extent of absorption of medicine that Concerta had," explained Dr. Andrew Adesman of the Steven and Alexandra Cohen Children's Medical Center, New York.
ADHD Treatment Lowers the Chances of Criminality
ADHD is quite common among children; if untested it can result in various health hazards. Adequate treatment is essential to fight the disorder and avoid indulging in any criminal act.
Advertisement
The FDA said the generics are no longer recommended as an automatic substitute for Concerta though they have no serious safety issues and can still be prescribed, but they may not work as effectively.
In some patients, the FDA found generics manufactured by Mallinckrodt and Kudco may deliver their dosage at a slower rate, lowering effectiveness. Concerta's manufacturer, Janssen, another version of the drug had no such problems.
Source: Medindia
Source: Medindia
Should Young ADHD Children be Medicated?
Children with ADHD who start medications early are likely to perform better academically, says study.
Advertisement
Drugs for ADHD Will Now Come With Suicide Risk Warnings in CanadaThough there is little evidence to establish that these drugs cause suicidal thoughts and behaviors, it's a distinct possibility they may contribute to the risk. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.